Human Cytomegalovirus Envelope Glycoprotein B (gB) - Pipeline Review, H1 2018

May 2018 | 48 pages | ID: HAB3FC870DFEN
Global Markets Direct

Abstracts

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Pipeline Review, H1 2018

SUMMARY

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Human Cytomegalovirus envelope glycoprotein B plays an important role in host cell entry and cell to cell virus transmission. It is involved in the initial attachment via binding to heparan sulfate together with the gM/gN complex that binds heparin with higher affinity. It interacts with host integrin ITGB1, PDGFRA and EGFR that likely serve as post attachment entry receptors. It participates in the fusion of viral and cellular membranes leading to virus entry into the host cell.

Human Cytomegalovirus Envelope Glycoprotein B (gB) pipeline Target constitutes close to 9 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 1, 1, 3 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Infectious Disease, Oncology and Women's Health which include indications Cytomegalovirus (HHV-5) Infections, Female Contraception, Gonorrhea, Human Immunodeficiency Virus (HIV) Infections (AIDS), Medulloblastoma, Recurrent Glioblastoma Multiforme (GBM), Simplexvirus (HSV) Infections and Trichomonas Vaginitis.

The latest report Human Cytomegalovirus Envelope Glycoprotein B (gB) - Pipeline Review, H1 2018, outlays comprehensive information on the Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for Human Cytomegalovirus Envelope Glycoprotein B (gB)
• The report reviews Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics and enlists all their major and minor projects
• The report assesses Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Human Cytomegalovirus Envelope Glycoprotein B (gB)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Human Cytomegalovirus Envelope Glycoprotein B (gB) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction
Global Markets Direct Report Coverage
Human Cytomegalovirus Envelope Glycoprotein B (gB) - Overview
Human Cytomegalovirus Envelope Glycoprotein B (gB) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Human Cytomegalovirus Envelope Glycoprotein B (gB) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Human Cytomegalovirus Envelope Glycoprotein B (gB) - Companies Involved in Therapeutics Development
Merck & Co Inc
Novartis AG
Trellis Bioscience Inc
Vakzine Projekt Management GmbH
VBI Vaccines Inc
Vical Inc
Human Cytomegalovirus Envelope Glycoprotein B (gB) - Drug Profiles
Bispecific Monoclonal Antibody to Target CD3 and gB for Cytomegalovirus (HHV-5) Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CSJ-148 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CyMVectin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cytomegalovirus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PPCM - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TRL-345 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VBI-1501 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VBI-1901 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VPM-2001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Human Cytomegalovirus Envelope Glycoprotein B (gB) - Dormant Products
Human Cytomegalovirus Envelope Glycoprotein B (gB) - Discontinued Products
Human Cytomegalovirus Envelope Glycoprotein B (gB) - Product Development Milestones
Featured News & Press Releases
May 10, 2018: VBI Vaccines Announces Positive Final Phase 1 Study Results of Preventative CMV Vaccine
Apr 17, 2018: VBI Vaccines Announces Positive DSMB Review in Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma (GBM) Patients
Jan 17, 2018: VBI Vaccines Announces Dosing of First GBM Patient in Phase 1/2a Clinical Study of VBI-1901
Nov 10, 2017: VBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1901, at SITC 2017
Oct 11, 2017: VBI Vaccines to Present Phase 1 CMV vaccine data at The World Vaccine Congress Europe 2017 in Barcelona
Aug 28, 2017: VBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1901, at The Immuno-Oncology Summit
Aug 15, 2017: VBI Vaccines Announces FDA Acceptance of Investigational New Drug Application for VBI-1901 to Treat Glioblastoma Multiforme
Jul 27, 2017: VBI Vaccines Announces Positive Interim Data from Phase 1 Study of Preventative CMV Vaccine
May 02, 2017: VBI Vaccines Provides Update on its Congenital CMV Phase I Clinical Study
Apr 05, 2017: VBI Vaccines to Present Update on VBI-1901 at the World Vaccine Congress
Nov 10, 2016: VBI Vaccines to Present at the Society of Neuro-Oncology Annual Meeting
Oct 11, 2016: VBI Vaccines Completes Pre-IND Meeting for its Glioblastoma Immunotherapy Candidate
Oct 05, 2016: VBI Vaccines to Present at the World Vaccine Congress Europe
Sep 20, 2016: VBI Vaccines Completes Enrollment of Participants in the Phase I Clinical Trial of its Preventative Cytomegalovirus Vaccine Candidate
Sep 01, 2016: VBI Vaccines to Present at the Vaccine Congress
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Merck & Co Inc, H1 2018
Pipeline by Novartis AG, H1 2018
Pipeline by Trellis Bioscience Inc, H1 2018
Pipeline by Vakzine Projekt Management GmbH, H1 2018
Pipeline by VBI Vaccines Inc, H1 2018
Pipeline by Vical Inc, H1 2018
Dormant Projects, H1 2018
Discontinued Products, H1 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

COMPANIES MENTIONED

Merck & Co Inc
Novartis AG
Trellis Bioscience Inc
Vakzine Projekt Management GmbH
VBI Vaccines Inc
Vical Inc